

Determination of "Proven Acceptable Independent Range" parameters in a Quality-By-Design approach

M. Claeys-Bruno¹, D. Manzon¹, B. Ghattas², S. Pierrot-Guedj³, M. Sergent¹

¹Institut Méditerranéen de Biodiversité et d'Ecologie marine et continentale, Aix-Marseille Université, UMR CNRS IRD Avignon Université, Site de l'Etoile, Marseille, France

²I2M UMR 7373, Aix Marseille Université, CNRS, Centrale Marseille, 13453 Marseille, France

³AZURAD, 33 place des Héros, 13013 Marseille

Keywords: Quality by Design, Design of Experiments, Response Surface Methodology, Design Space, Proven Acceptable Independent Range

1 Introduction

In pharmaceutical studies, the Quality by Design (QbD) approach ^{1,2,3} is increasingly being implemented to improve product development. Product quality is tested at each step of the manufacturing process, allowing a better process understanding and a better risk management, thus avoiding manufacturing defects.




Figure 1: Elements of QbD approach

2 Theory

A key element of QbD is the construction of a Design Space (DS)⁴, i.e., a region in which the probability that the specifications on the output parameters will be met is imposed. Among the various possible construction methods, Designs of Experiments (DoE), and more precisely Response Surface Methodology, represent a perfectly adapted tool.




Figure 2: Illustration of QbD concepts in experimental domain - 2D representation

3 Results and discussion

The DS obtained may have any geometrical shape; consequently, the acceptable variation range of an input may depend on the value of other inputs. However, the experimenters would like to directly know the variation range of each input so that their variation domains are independent. In this context, we developed a method to determine the "Proven Acceptable Independent Range" (PAIR). It consists of looking for all the hyper polyhedra included in the multidimensional DS and selecting a hyper polyhedron according to various strategies.

We will illustrate the performance of our method on different DoE cases.

4 References

- [1] Anonymous. ICH Q8 (R2) Pharmaceutical development. European Medicines Agency. Published September 17, 2018. Accessed January 4, 2022. <https://www.ema.europa.eu/en/ich-q8-r2-pharmaceutical-development>
- [2] Sarasija S, Roy S, K. A. Quality by design: An overview. *Indian Drugs*. 2015;Volume No. 52:Page No. 5-11. doi:10.53879/id.52.02.p0005
- [3] Pramod K, Tahir MA, Charoo NA, Ansari SH, Ali J. Pharmaceutical product development: A quality by design approach. *Int J Pharm Investig*. 2016;6(3):129-138. doi:10.4103/2230-973X.187350
- [4] Manzon D, Claeys-Bruno M, Declomesnil S, Carité C, Sergent M. Quality by Design: Comparison of Design Space construction methods in the case of Design of Experiments. *Chemom Intell Lab Syst*. 2020;200:104002. doi:10.1016/j.chemolab.2020.104002